Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This narrative review highlights that endurance, skill-oriented athletes, and physique-oriented competitors such as bodybuilders face accelerated degradation of fillers and botulinum neurotoxin due to elevated basal metabolic rates and other factors, and raised concerns about psychological conditions like body dysmorphic disorder in these populations.

This study reported that a single-session scalp procedure combining several components, including PRP and botulinum toxin, was associated with significant improvements in hair thickness and reduced vellus hair proportion in androgenetic alopecia patients, although further controlled trials are needed to establish causation.

This study highlights that modern facial rejuvenation techniques have shifted toward minimally invasive injectable methods, with botulinum toxin and hyaluronic acid fillers effectively reducing wrinkles, enhancing facial features, and temporarily addressing age-related facial changes as alternatives to more invasive surgery.

This review explores the complex pathophysiology of androgenetic alopecia, highlighting genetic factors, androgen metabolism, and emerging therapies such as platelet-rich plasma and low-level laser therapy, but notes that no ultimate cure exists and treatments focus on slowing progression and promoting hair growth.

This review provides a clinical guide for safely using dermo-aesthetic treatments to improve the quality of life for oncology patients dealing with treatment-related side effects, emphasizing the importance of consulting with an oncologist before undergoing such procedures.

This study evaluated the molecular mechanisms, clinical efficacy, and safety of off-label therapies for male androgenetic alopecia and determined the relative efficacy of these therapies compared to topical minoxidil through a network meta-analysis.

This review identified emerging therapies for androgenetic alopecia, such as low-dose oral minoxidil and stem cell-based treatments, which show promise for improved hair loss management but require standardized protocols and large-scale trials for further validation.

This study's network meta-analysis reported that botulinum injection combined with red laser and topical minoxidil is most effective for increasing hair density in androgenetic alopecia when using low-level laser therapy.

This review article examines current drugs for androgenetic alopecia, focusing on their mechanisms and clinical efficacy, noting that while finasteride and minoxidil are commonly approved treatments, new drugs targeting different pathogenic pathways have emerged, offering a broader understanding and reference for AGA treatment options.

This study found that a single session of botulinum toxin, whether administered subcutaneously or combined intramuscularly and subcutaneously, did not significantly improve hair density or hair quality in men with androgenetic alopecia after six months.

This review found that mesotherapy could improve hair density and reduce hair fall in androgenetic alopecia, especially when combined with other treatments, but lacks standardized protocols and long-term safety data.

This review discusses the various therapeutic uses of Botulinum Toxin Type A and reports high levels of patient satisfaction with minimal adverse effects across several conditions, emphasizing its potential therapeutic importance.

This study reports that non-surgical treatments like triamcinolone acetonide and Botulinum toxin Type A reduced keloid volume by up to 80% in children, with combination therapies being safer and having fewer side effects.

This source reviews clinical research progress on injection therapies for androgenetic alopecia, highlighting that methods like platelet derivatives, botulinum toxin, and stem cells may offer precise hair follicle targeting and reduced side effects compared to traditional treatments.

In this case report, the authors observed that onabotulinum toxin A therapy, extended to areas around traumatic excoriations and alopecia, resulted in notable healing and hair regrowth in a patient with trigeminal trophic syndrome and trichotillomania.

This study discusses trichodynia, a painful scalp condition often linked to various forms of alopecia and psychiatric comorbidities, highlighting its clinical diagnosis, lack of specific treatments, and suggesting the need for more research to explore effective therapies.

This review found that various dermatological procedures for Seborrheic Dermatitis, such as phototherapy and laser treatments, showed significant efficacy in small cohorts with high patient satisfaction, but highlighted the need for further research to standardize protocols and evaluate long-term outcomes.

This study reviewed recent advancements in using botulinum toxin for treating androgenetic alopecia and emphasized the need for further research to determine the most effective injection sites and depths, as current strategies show inconsistent results.

This review article highlights the complexity of treating folliculitis decalvans, emphasizing the role of systemic antibiotics like rifampicin and clindamycin as common treatments, while also discussing promising novel therapies, including biological agents, that require further clinical trials to assess their effectiveness and safety.

The study concluded that dutasteride 0.5 mg daily for 24 weeks was the most effective monotherapy for increasing hair density in men with androgenetic alopecia, compared to other interventions.

This source reports that for treating keloids and hypertrophic scars, combination pharmacotherapy targeting multiple sites is generally more effective than using a single drug, though outcomes of individual therapies vary and the development of satisfying treatments is ongoing.

In this narrative review, the authors explored various rehabilitative techniques, including injections and physical therapies, that may enhance aesthetics and psychosocial wellbeing in patients with disabilities, emphasizing a multidisciplinary approach to improve both functional and cosmetic outcomes.

In this case report, off-label onabotulinumtoxin-A was successfully used to treat trichodynia, a painful scalp sensation associated with hair loss, in a patient unresponsive to conventional therapies.

This source reviews popular cosmeceutical ingredients for skin care, noting that while they are popular among consumers for anti-aging benefits, many lack robust clinical evidence for their efficacy and safety, as they are not regulated by the FDA.

This review discusses the non-cosmetic uses of botulinum neurotoxin A, including its effectiveness for idiopathic hyperhidrosis and potential use for androgenic alopecia, and reports no new clinical results; the authors highlight the need for more clinical trials.

This review suggests that dermatological cosmetic procedures can be safely performed on dark-complexioned skin with appropriate treatment adjustments, highlighting the need for careful consideration to prevent adverse effects.

This study reviewed research on the psychosocial effects of gender-affirming dermatology treatments in transgender populations, finding mostly positive associations but noting significant limitations and the need for more comprehensive studies to clearly understand these effects.

This publication reviews various treatment options for male androgenetic alopecia, including minoxidil, 5a-reductase inhibitors, tretinoin, botulinum toxin, microRNA, and osteopontin, highlighting the limited proven treatments and ongoing research to discover and optimize effective therapies.

This study reviews the increasing interest and reduced stigma surrounding men's plastic and cosmetic surgery, focusing on procedures like neuromodulator injections and hair transplants, highlighting their gender-specific aspects over the past decade.

This review highlights the dermatological needs of transgender and gender diverse individuals in Australia, emphasizing the role of dermatologists in managing skin and hair conditions related to gender affirmation and hormone therapy.